Oveporexton Trials in Narcolepsy Type 1

<p>Two phase 3 clinical trials evaluated the efficacy and safety of <strong>oveporexton</strong>, an oral orexin receptor 2-selective agonist, for treating <strong>narcolepsy type 1</strong> over a 12-week period. Participants receiving twice-daily oveporexton experienced significant improvements in <strong>mean sleep latency</strong>, <strong>excessive daytime sleepiness</strong>, and the <strong>weekly cataplexy rate</strong> compared to those on a placebo. While adverse events such as <strong>increased urinary frequency</strong> and <strong>transient insomnia</strong> were more common in the treatment groups, most side effects were mild to moderate in severity. These findings confirm that addressing the underlying <strong>orexin deficiency</strong> successfully alleviates core narcolepsy symptoms and enhances overall quality of life.</p>